Emmanuelle Charpentier, Jennifer Doudna and Feng Zhang are three of the pioneers in the use of CRISPR-Cas9. Doudna and Zhang helped launch Editas Medicine in 2013, but Doudna left the following year to join Intellia Therapeutics.
Intellia Therapeutics currently has a valuation of more than $ 700 million. Editas is worth more than $ 1.3 billion. As Chief Scientist and co-discoverer of CRISPR, Jennifer Doudna clearly has a significant number of actions in Editas and Intellia.
Not surprisingly, Doudna issued a statement condemning the controversy over the editing of human embryo genes.
It is essential that this news does not detract from the many important clinical efforts to use CRISPR technology to treat and cure diseases in adults and children. Public and transparent discussions on the many uses of genome editing technology should continue, as will be the case over the next three days at the Hong Kong Human Genome Publishing Summit.
The genetic editing of the embryo by humans is very controversial. A large shareholder in CRISPR companies hates any controversial use of CRISPR that may trigger negative reactions against CRISPR activities.